Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mol Ther ; 31(3): 686-700, 2023 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-36641624

RESUMO

Several studies have shown the influence of commensal microbes on T cell function, specifically in the setting of checkpoint immunotherapy for cancer. In this study, we investigated how vancomycin-induced gut microbiota dysbiosis affects chimeric antigen receptor (CAR) T immunotherapy using multiple preclinical models as well as clinical correlates. In two murine tumor models, hematopoietic CD19+-A20 lymphoma and CD19+-B16 melanoma, mice receiving vancomycin in combination with CD19-directed CAR T cell (CART-19) therapy displayed increased tumor control and tumor-associated antigens (TAAs) cross-presentation compared with CART-19 alone. Fecal microbiota transplant from human healthy donors to pre-conditioned mice recapitulated the results obtained in naive gut microbiota mice. Last, B cell acute lymphoblastic leukemia patients treated with CART-19 and exposed to oral vancomycin showed higher CART-19 peak expansion compared with unexposed patients. These results substantiate the role of the gut microbiota on CAR T cell therapy and suggest that modulation of the gut microbiota using vancomycin may improve outcomes after CAR T cell therapy across tumor types.


Assuntos
Microbioma Gastrointestinal , Receptores de Antígenos Quiméricos , Humanos , Camundongos , Animais , Receptores de Antígenos de Linfócitos T/genética , Apresentação Cruzada , Vancomicina/farmacologia , Imunoterapia , Linfócitos T , Imunoterapia Adotiva/métodos , Receptores de Antígenos Quiméricos/genética , Antígenos CD19
2.
Nat Protoc ; 19(4): 1053-1082, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38212641

RESUMO

The pathogenesis of cancer and cardiovascular diseases is subjected to spatiotemporal regulation by the tissue microenvironment. Multiplex visualization of the microenvironmental components, including immune cells, vasculature and tissue hypoxia, provides critical information underlying the disease progression and therapy resistance, which is often limited by imaging depth and resolution in large-volume tissues. To this end, light sheet fluorescence microscopy, following tissue clarification and immunostaining, may generate three-dimensional high-resolution images at a whole-organ level. Here we provide a detailed description of light sheet fluorescence microscopy imaging analysis of immune cell composition, vascularization, tissue perfusion and hypoxia in mouse normal brains and hearts, as well as brain tumors. We describe a procedure for visualizing tissue vascularization, perfusion and hypoxia with a transgenic vascular labeling system. We provide the procedures for tissue collection, tissue semi-clearing and immunostaining. We further describe standard methods for analyzing tissue immunity and vascularity. We anticipate that this method will facilitate the spatial illustration of structure and function of the tissue microenvironmental components in cancer and cardiovascular diseases. The procedure requires 1-2 weeks and can be performed by users with expertise in general molecular biology.


Assuntos
Neoplasias Encefálicas , Doenças Cardiovasculares , Animais , Camundongos , Microscopia de Fluorescência/métodos , Imageamento Tridimensional/métodos , Análise Espacial , Hipóxia , Microambiente Tumoral
3.
STAR Protoc ; 5(1): 102898, 2024 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-38367235

RESUMO

The efficacy of chimeric antigen receptor (CAR) T cell immunotherapy is limited by insufficient infiltration and activation of T cells due to the immunosuppressive tumor microenvironment. Preclinical studies with optimized mouse CAR T cells in immunocompetent mouse cancer models will help define the mechanisms underlying immunotherapy resistance. Here, we present a protocol for preparing mouse T cells and generating CAR T cells. We then detail procedures for testing their therapeutic efficacy and tracking them in a syngeneic mouse glioma model. For complete details on the use and execution of this protocol, please refer to Zhang et al.1.


Assuntos
Glioma , Receptores de Antígenos Quiméricos , Animais , Camundongos , Imunoterapia Adotiva/métodos , Receptores de Antígenos Quiméricos/genética , Imunoterapia , Linfócitos T , Glioma/terapia , Modelos Animais de Doenças , Microambiente Tumoral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA